Skip to content

Self-help Smartphone-delivered Cognitive Behavioral Therapy for Insomnia in People With Depression and Insomnia

Parallel Group Randomized Controlled Trial on the Effect of a Smartphone-delivered Cognitive Behavioral Therapy for Insomnia on People With Major Depression and Insomnia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04228146
Enrollment
285
Registered
2020-01-14
Start date
2019-03-19
Completion date
2021-06-30
Last updated
2020-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Sleep Initiation and Maintenance Disorders

Brief summary

This randomized controlled trial aims to examine the effectiveness of a self-help smartphone-delivered cognitive behavioral therapy for insomnia, compared to a waitlist control, in treating people with major depression and insomnia in Hong Kong.

Detailed description

Depression is a major public health concern. Emerging research has shown that cognitive behavioral therapy for insomnia (CBT-I) is effective in treating individuals with comorbid insomnia and depression. Traditional face-to-face CBT-I encounters many obstacles related to feasibility, accessibility, and help-seeking stigma. CBT-I delivered via smartphone application could be a potential solution. This two-arm parallel randomized controlled trial (RCT) aims to examine the effectiveness of a smartphone-based self-help CBT-I with a waitlist control group in treating people with major depression and insomnia in Hong Kong. Participants complete an online rapid screening, followed by a telephone diagnostic interview. Those who meet the eligibility criteria are randomized in a ratio of 1:1 to receive either CBT-I immediately or to a waitlist control condition. The CBT-I consists of six weekly modules and is delivered through a smartphone application known as proACT-S. An online randomized algorithm is used to perform randomization to ensure allocation concealment. The primary outcomes are changes over the measurement points in sleep quality, insomnia severity and depression severity. The secondary outcomes include changes over the measurement points in anxiety, subjective health, treatment expectancy, and acceptability of treatment. Assessments are administered at baseline, post-intervention, and 6-week follow up. The recruitment is underway. Important adverse events, if any, are documented. Multilevel linear mixed model based on intention-to-treat principle will be conducted to examine the effectiveness of the CBT-I intervention Participants in the CBT-I condition will start CBT-I immediately after randomization; while participants in the waitlist control group will start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment. It is hypothesized that, after the intervention, participants in the CBT-I condition will report a greater decrease in poor sleep quality, depression severity and insomnia severity than those in the waitlist control condition. It is also hypothesized that the reduction in poor sleep quality, depression severity and insomnia severity observed in the CBT-I condition will be maintained at 6-week follow-up. Furthermore, it is hypothesized that participants in the waitlist control condition will report a significant decrease in poor sleep quality, depression severity and insomnia severity after receiving CBT-I.

Interventions

BEHAVIORALCognitive Behavioral Therapy for Insomnia

Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes.

OTHERWaitlist Control

Delay access to the self-help CBT-I treatment.

Sponsors

The University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Stage 1 Screening (Online Survey) Inclusion Criteria: * Hong Kong residents * age ≥ 18 years * predominant complaint of difficulty initiating or maintaining sleep or early morning awakening or non-restorative sleep with associated distress or impairment in social, occupational and other important areas of functioning for at least three nights per week for at least three months * Insomnia Severity Index score ≥ 8 * Patient Health Questionnaire (PHQ-9) score ≥ 10 * being able to read Chinese and type Chinese or English * have a smartphone device (iOS or Android operating system) with Internet access * have a regular email address * willing to give informed consent and comply with the trial protocol Stage 1 Screening (Online Survey)

Exclusion criteria

* Beck Depression Inventory II (BDI-II) suicidal ideation score ≥ 2 * receiving concurrent psychological treatment at least once per month * former proACT-S pilot clinical trial participants * currently taking prescribed psychiatric drugs such as antidepressants, tranquilizers, sleeping pills regularly * carrying a diagnosis of psychosis or schizophrenia * participating in any other academic studies or clinical trials related to insomnia and/or depression Stage 2 Screening (Telephone Diagnostic Interview) Inclusion Criteria * difficulty initiating sleep, maintaining sleep, or early-morning awakening with inability to return to sleep at least once in the past two weeks * International Statistical Classification of Diseases and Related Health Problems - Tenth Revision diagnosis of depression (F32.00, F32.01, F32.10, F32.11, F32.2) Stage 2 Screening (Telephone Diagnostic Interview)

Design outcomes

Primary

MeasureTime frameDescription
Changes over the measurement points in Center for Epidemiologic Studies Depression ScaleBaseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures the severity of depressive symptoms during the past week. Range from 0 to 60, where a higher value indicates more severe depressive symptoms.
Changes over the measurement points in Pittsburgh Sleep Quality IndexBaseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures sleep quality and disturbances during the past month. It has seven components, namely, sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of hypnotics, and daytime dysfunction. Range from 0 to 21, where a higher value indicates poorer sleep quality.
Changes over the measurement points in Insomnia Severity IndexBaseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures the severity of insomnia symptoms and the associated daytime impairment over the past two weeks. Range from 0 to 21, where a higher value indicates more severe insomnia symptoms.

Secondary

MeasureTime frameDescription
Changes over measurement points in SF-12 Version 1 Physical ScaleBaseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures subjective physical health status during the past four weeks. A higher value indicates better subjective physical health.
Changes over measurement points in SF-12 Version 1 Mental ScaleBaseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures subjective physical health status during the past four weeks. A higher value indicates better subjective mental health.
Changes over measurement points in Hospital Anxiety and Depression Scale - Anxiety subscaleBaseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures severity of anxiety symptoms during the past week. Range from 0 to 21, where a higher value indicates more severe anxiety symptoms.

Other

MeasureTime frameDescription
Clinical comorbidityStage 2 screening (telephone diagnostic interview): Up to 3 months after enrollmentMeasures current diagnosis of four major comorbidities (generalized anxiety disorder, phobias, obsessive compulsive disorder, and panic disorder).
DemographicsStage 1 screening (online survey): First day of enrollmentMeasures Participants' age, education level, marital status, occupation, and gender
Changes over measurement points in Modified Credibility/Expectancy Questionnaire (Credibility Scores)Baseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures participants' perceived treatment credibility. A higher value indicates higher levels of perceived treatment credibility.
Changes over measurement points in Modified Credibility/Expectancy Questionnaire (Expectancy Scores)Baseline, post-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures participants' perceived treatment expectancy. A higher value indicates higher levels of perceived treatment expectancy.
Modified Participant Acceptability/Usability Rating ScalePost-intervention: 6 weeks after CBT-I initiation, 6-week follow upMeasures participants' subjective evaluation of the treatment received via the smartphone application. A higher value indicates higher levels of perceived treatment acceptability.

Countries

China

Contacts

Primary ContactChristian S Chan, PhD
shaunlyn@hku.hk+852 39177121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026